Disease-free and overall survival were comparable between paclitaxel- and cisplatin-based heated chemotherapy regimens in ...

When Nikki Myers, 33, found a lump in her neck last fall, she visited an urgent care clinic. She learned she had ovarian ...

US ovarian cancer mortality rates declined from 1999 to 2020, but significant disparities remain across age, race, and geographic regions, highlighting the need for targeted public health efforts.

A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and ...

Obesity, a growing global epidemic, is identified as a significant, modifiable risk factor for ovarian cancer, a deadly ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

New clinical trials are advancing in hard-to-treat cancers, offering targeted and less toxic options for patients with ...

("LIXTE” or the "Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that the ...

Researchers identify PPP2R1A gene mutations as a new marker linked to better immunotherapy response and survival in ovarian ...

Fat tissue secretes hormones known as adipokines. Patients with obesity have a larger amount of leptin than a normal ...